These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32710713)

  • 1. Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium.
    Okada K; Soejima T; Sakamoto H; Hirato J; Hara J
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28572. PubMed ID: 32710713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan.
    Yamasaki K; Okada K; Soejima T; Sakamoto H; Hara J
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28012. PubMed ID: 31544362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study.
    Wahba HA; Abu-Hegazy M; Wasel Y; Ismail EI; Zidan AS
    J BUON; 2013; 18(2):425-9. PubMed ID: 23818356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
    Sung KW; Lim DH; Son MH; Lee SH; Yoo KH; Koo HH; Kim JH; Suh YL; Joung YS; Shin HJ
    Neuro Oncol; 2013 Mar; 15(3):352-9. PubMed ID: 23258845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy and overall survival in adult medulloblastoma.
    Kann BH; Lester-Coll NH; Park HS; Yeboa DN; Kelly JR; Baehring JM; Becker KP; Yu JB; Bindra RS; Roberts KB
    Neuro Oncol; 2017 Feb; 19(2):259-269. PubMed ID: 27540083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
    Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
    Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
    Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
    Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients.
    Massimino M; Sunyach MP; Barretta F; Gandola L; Garegnani A; Pecori E; Spreafico F; Bonneville-Levard A; Meyronet D; Mottolese C; Boschetti L; Biassoni V; Schiavello E; Giussani C; Carrabba G; Diletto B; Pallotti F; Stefini R; Ferrari A; Terenziani M; Casanova M; Luksch R; Meazza C; Podda M; Chiaravalli S; Puma N; Bergamaschi L; Morosi C; Calareso G; Giangaspero F; Antonelli M; Buttarelli FR; Frappaz D
    J Neurooncol; 2020 Jul; 148(3):619-628. PubMed ID: 32567042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
    Packer RJ; Gajjar A; Vezina G; Rorke-Adams L; Burger PC; Robertson PL; Bayer L; LaFond D; Donahue BR; Marymont MH; Muraszko K; Langston J; Sposto R
    J Clin Oncol; 2006 Sep; 24(25):4202-8. PubMed ID: 16943538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.
    Yoon JH; Park KD; Kang HJ; Kim H; Lee JW; Kim SK; Wang KC; Park SH; Kim IH; Shin HY
    World J Pediatr; 2017 Aug; 13(4):367-373. PubMed ID: 28550392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience.
    Atalar B; Ozsahin M; Call J; Napieralska A; Kamer S; Villa S; Erpolat P; Negretti L; Lassen-Ramshad Y; Onal C; Akyurek S; Ugurluer G; Baumert BG; Servagi-Vernat S; Miller RC; Ozyar E; Sio TT
    Radiother Oncol; 2018 Apr; 127(1):96-102. PubMed ID: 29373196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
    Lee JW; Lim DH; Sung KW; Cho HW; Ju HY; Hyun JK; Yoo KH; Koo HH; Suh YL; Joung YS; Shin HJ
    Cancer Med; 2020 Aug; 9(16):5807-5818. PubMed ID: 32608158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
    Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
    Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
    Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
    Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
    J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors.
    Murphy ES; Merchant TE; Wu S; Xiong X; Lukose R; Wright KD; Qaddoumi I; Armstrong GT; Broniscer A; Gajjar A
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e655-60. PubMed ID: 22768993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.
    von Bueren AO; von Hoff K; Pietsch T; Gerber NU; Warmuth-Metz M; Deinlein F; Zwiener I; Faldum A; Fleischhack G; Benesch M; Krauss J; Kuehl J; Kortmann RD; Rutkowski S
    Neuro Oncol; 2011 Jun; 13(6):669-79. PubMed ID: 21636711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
    Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
    Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk/metastatic medulloblastoma in a resource-limited setting.
    Gupta T; Sinha S; Chinnaswamy G; Vora T; Prasad M; Bhat V; Goda JS; Krishnatry R; Chatterjee A; Epari S; Sahay A; Moiyadi A; Shetty P; Patil V; Khatua S; Jalali R; Kurkure P
    Pediatr Blood Cancer; 2021 May; 68(5):e28925. PubMed ID: 33533557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.